J. B. Chemicals & Pharmaceuticals Beheer
Beheer criteriumcontroles 2/4
Momenteel beschikken wij niet over voldoende informatie over de CEO.
Belangrijke informatie
Nikhil Chopra
Algemeen directeur
₹71.3m
Totale compensatie
| Percentage CEO-salaris | 49.2% |
| Dienstverband CEO | 3.9yrs |
| Eigendom CEO | n/a |
| Management gemiddelde ambtstermijn | 1.8yrs |
| Gemiddelde ambtstermijn bestuur | 4.1yrs |
Recente managementupdates
Recent updates
J. B. Chemicals & Pharmaceuticals Limited's (NSE:JBCHEPHARM) Business Is Yet to Catch Up With Its Share Price
Sep 24
Most Shareholders Will Probably Agree With J. B. Chemicals & Pharmaceuticals Limited's (NSE:JBCHEPHARM) CEO Compensation
Aug 15J. B. Chemicals & Pharmaceuticals Limited Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
Aug 11These 4 Measures Indicate That J. B. Chemicals & Pharmaceuticals (NSE:JBCHEPHARM) Is Using Debt Reasonably Well
Jun 28J. B. Chemicals & Pharmaceuticals Limited (NSE:JBCHEPHARM) Not Flying Under The Radar
Apr 19J. B. Chemicals & Pharmaceuticals Limited Just Missed Earnings - But Analysts Have Updated Their Models
Feb 09J. B. Chemicals & Pharmaceuticals Limited (NSE:JBCHEPHARM) Not Flying Under The Radar
Dec 22We Think J. B. Chemicals & Pharmaceuticals (NSE:JBCHEPHARM) Can Stay On Top Of Its Debt
Nov 29J. B. Chemicals & Pharmaceuticals' (NSE:JBCHEPHARM) Dividend Will Be Increased To ₹9.25
Aug 03J. B. Chemicals & Pharmaceuticals (NSE:JBCHEPHARM) Is Due To Pay A Dividend Of ₹8.50
Feb 11Is J. B. Chemicals & Pharmaceuticals (NSE:JBCHEPHARM) Using Too Much Debt?
Dec 03A Look At The Intrinsic Value Of J. B. Chemicals & Pharmaceuticals Limited (NSE:JBCHEPHARM)
Sep 21J. B. Chemicals & Pharmaceuticals (NSE:JBCHEPHARM) Seems To Use Debt Quite Sensibly
Aug 03Estimating The Fair Value Of J. B. Chemicals & Pharmaceuticals Limited (NSE:JBCHEPHARM)
Jun 15Does J. B. Chemicals & Pharmaceuticals (NSE:JBCHEPHARM) Have A Healthy Balance Sheet?
Mar 29J. B. Chemicals & Pharmaceuticals (NSE:JBCHEPHARM) Has Re-Affirmed Its Dividend Of ₹8.50
Feb 16With EPS Growth And More, J. B. Chemicals & Pharmaceuticals (NSE:JBCHEPHARM) Is Interesting
Jan 27Analyse CEO-vergoeding
| Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | ₹6b |
| Mar 31 2024 | ₹71m | ₹35m | ₹6b |
| Dec 31 2023 | n/a | n/a | ₹5b |
| Sep 30 2023 | n/a | n/a | ₹5b |
| Jun 30 2023 | n/a | n/a | ₹4b |
| Mar 31 2023 | ₹65m | ₹37m | ₹4b |
| Dec 31 2022 | n/a | n/a | ₹4b |
| Sep 30 2022 | n/a | n/a | ₹4b |
| Jun 30 2022 | n/a | n/a | ₹4b |
| Mar 31 2022 | ₹59m | ₹18m | ₹4b |
| Dec 31 2021 | n/a | n/a | ₹4b |
| Sep 30 2021 | n/a | n/a | ₹5b |
| Jun 30 2021 | n/a | n/a | ₹4b |
| Mar 31 2021 | ₹32m | ₹7m | ₹4b |
Compensatie versus markt: De totale vergoeding ($USD 848.28K ) Nikhil } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de Indian markt ($USD 604.06K ).
Compensatie versus inkomsten: De vergoeding van Nikhil is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.
CEO
Nikhil Chopra (51 yo)
3.9yrs
Tenure
₹71,338,000
Compensatie
Mr. Nikhil Ashokkumar Chopra serves as Chief Executive Officer and Whole-Time Director at J. B. Chemicals & Pharmaceuticals Limited since December 23, 2020 and has been its Director since May 10, 2020. He...
Leiderschapsteam
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| CEO & Whole-Time Director | 3.9yrs | ₹71.34m | geen gegevens | |
| Assistant Vice President – Human Resource | no data | ₹10.48m | 0.0025% ₹ 7.1m | |
| Chief Financial Officer | less than a year | ₹12.74m | geen gegevens | |
| President of Operations | no data | ₹28.44m | geen gegevens | |
| Vice President of Finance & Accounts | no data | ₹9.48m | geen gegevens | |
| Vice President of Information & Technology | 9.8yrs | ₹10.70m | geen gegevens | |
| Vice President of HR & Administration | 8.2yrs | ₹13.80m | 0.00084% ₹ 2.4m | |
| Vice President of Legal | 1.8yrs | ₹11.49m | geen gegevens | |
| President of Global Business | no data | ₹42.09m | 0.0039% ₹ 11.1m | |
| Executive Vice President of Operations of Daman | 1.3yrs | ₹17.24m | 0.0048% ₹ 13.9m | |
| Executive Vice President of Supply Chain Operations | no data | ₹19.54m | geen gegevens | |
| Executive Vice President | less than a year | ₹18.12m | geen gegevens |
1.8yrs
Gemiddelde duur
51yo
Gemiddelde leeftijd
Ervaren management: Het managementteam van JBCHEPHARM wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 1.8 jaar), wat duidt op een nieuw team.
Bestuursleden
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| CEO & Whole-Time Director | 4.1yrs | ₹71.34m | geen gegevens | |
| Chairman of Biotech Laboratories (Pty ) Ltd | no data | geen gegevens | geen gegevens | |
| Non-Executive Independent Chairman | less than a year | geen gegevens | geen gegevens | |
| Non-Executive & Independent Director | 4.3yrs | ₹7.50m | geen gegevens | |
| Non-Executive Director | 4.3yrs | geen gegevens | geen gegevens | |
| Non-Executive & Non-Independent Director | less than a year | geen gegevens | geen gegevens | |
| Non-Executive Director | 3.8yrs | geen gegevens | geen gegevens | |
| Non-Executive & Independent Director | 4.3yrs | ₹7.50m | geen gegevens |
4.1yrs
Gemiddelde duur
64.5yo
Gemiddelde leeftijd
Ervaren bestuur: De raad van bestuur van JBCHEPHARM wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.1 jaar).